

1 **A cross-sectional questionnaire-based landscaping of female infertility reveals**
2 **genital Infections as a major contributor to reproductive tract anomalies,**
3 **menstrual disorders, and infertility**

4

5 Naresh Patnaik¹, Uttam Sarkar², Malathi Jojula³, Hema Vaddiraju⁴, Ruchi Jain Dey^{1, *}

6

7 **Author Affiliations:**

8 ¹Department of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana
9 State- 500 078, India

10 ²West Bengal University of Animal and Fishery Sciences, Department of Animal
11 Genetics and Breeding, West Bengal – 700037, India

12 ³Department of Microbiology, Sri Shivani College of Pharmacy, Mulugu Road,
13 Warangal, Telangana State – 506002, India

14 ⁴Curewell Hospital, Srinivasa Colony, Warangal, Telangana State – 506007, India

15

16 ***Corresponding author**

17 **Email for correspondence:** ruchij80@hyderabad.bits-pilani.ac.in

18

19 **Abstract**

20 **Objectives:** Female infertility is a global health concern. The association of genital
21 infections with female infertility is neglected due to their chronic but asymptomatic
22 nature. Lack of routine diagnosis and delay in treatment further causes intractable
23 pathological sequelae and consequential infertility. This study aims to identify the most
24 significant prognostic symptoms of genital infection(s) that correlate strongly with
25 reproductive tract anomalies, menstrual disorders, and infertility.

26 **Methods:** We designed a detailed questionnaire and conducted a cross-sectional
27 study with 100 female subjects, categorized into infertile ($n_1 = 62$) and healthy groups
28 ($n_2 = 38$). The data collected was documented and statistically analyzed.

29 **Results:** This study highlights an early onset of infertility (21-30 years). Almost 27%
30 of the infertile subjects are symptomatic for genital infections and ~42% exhibit
31 menstrual irregularities. Polycystic ovarian syndrome/disease (PCOS/PCOD, ~30%),
32 are observed to be the most predominant disorders followed by endometrial disorders
33 (~10%) and tubal damage (~8%) in infertile subjects. A multivariate correlation analysis
34 revealed a highly significant ($p \leq 0.05$) and strong association ($0.15 < \Phi \leq 1.0$) between
35 menstrual disorders, endometrial disorders, uterine/tubal blockage, and hormonal
36 disruption with infection-associated symptoms, such as vaginitis, cervicitis, pelvic
37 inflammatory disorder (PID), dyspareunia, tuberculosis (TB), urinary tract infection
38 (UTI), sperm, and semen abnormalities.

39 **Conclusions:** Our study reveals genital infections to be a significant contributor to
40 female infertility. The questionnaire designed here offers a useful tool for self or clinical
41 assessment and may help in timely prognosis/diagnosis of genital infections which
42 may contribute to improved management of reproductive health and fertility.

43

44 **Keywords:** Female infertility, genital infections, female genital tuberculosis (FGTB),
45 menstrual disorders, PCOS & PCOD, Uterine and tubal blockage, endometrial
46 disorders, endometriosis.

47

48 **Synopsis:** The study reveals impact of genital infections on female infertility and offers
49 a comprehensive questionnaire-based tool for an early self/clinical prognosis of
50 infection induced infertility.

51

52 **Introduction:**

53 Infertility and menstrual disorders are some of the major health concerns affecting
54 women worldwide. A recent report by WHO estimates, that approximately 1 in 6
55 women (17.5% of the adult population) are affected by infertility [1-3], and the rates of
56 infertility are comparable across low-, middle- and high-income countries [3]. The
57 significant number of individuals impacted by infertility, menstrual disorders, and
58 reproductive tract anomalies highlights the necessity to broaden the availability of
59 reproductive health care and prioritization of this matter in health research and policy
60 [3]. This will ensure the availability of secure, efficient, and reasonably priced treatment
61 modalities for women suffering from these disorders and couples desiring to become
62 parents [2, 3].

63 Infertility is a disease of both the male and/or female reproductive system and
64 is defined as the inability to conceive after a year of regular, unprotected sexual
65 intercourse [2, 3]. It is a complex and multi-factorial disorder that can result from
66 numerous factors such as genetic, environment, nutrition, infections, and lifestyle [4].
67 In the absence of regular reproductive health assessment due to cultural/financial
68 constraints and societal stigma, reproductive health issues remain largely ignored.
69 This leads to delayed diagnosis and treatment of these disorders causing infertility in
70 the long run [2]. Infertility has the potential to cause substantial emotional and
71 economic strain on the families and impacts individuals' mental and psychosocial
72 welfare. Countless individuals encounter overwhelming medical expenses during
73 infertility treatments, leading to healthcare-induced poverty [2, 5-7].

74 In tropical countries like India, where tuberculosis (TB) and other infectious
75 diseases are widespread, the role of infectious diseases in causing infertility becomes
76 a prominent consideration as indicated by several studies [5, 8-10]. Genital infections

77 (sexually transmitted, postpartum, post-abortion infections and secondary infections
78 e.g., TB) may cause a wide spectrum of conditions like vaginitis, cervicitis,
79 dyspareunia and PID [11, 12], endometriosis and other endometrial disorders [5, 13],
80 PCOS/PCOD, ovarian atresia or cysts and anovulation [14, 15]. These infections are
81 generally chronic in nature and cause inflammation and irreversible scarring of the
82 reproductive tract leading to sub-fertility, infertility, recurrent abortions, low birth weight,
83 pre-term birth, stillbirth, maternal and infant mortality [5, 9, 10]. For instance, female
84 genital tuberculosis (FGTB) is estimated to be responsible for 6-25% of female
85 infertility cases in India [5, 16-19]. FGTB can occur as a primary infection or as a result
86 of secondary spread from infected lungs or reactivation of the latent infection and may
87 cause reduced ovarian reserve (ovarian atresia), PCOS/PCOD, fallopian tube, and
88 uterine damage (e.g. adhesions, cysts and endometrial disorders), pregnancy failures
89 and infertility. The treatment of FGTB involves a combination of anti-TB drugs and
90 surgical intervention(s), however, the success rates of these treatments in terms of the
91 improvement in fertility vary depending on the severity of the reproductive tract
92 damage [20-22]. Previous research also links bacterial vaginosis (BV) to PID and
93 endometritis with consequential infertility [11]. Endometrial presence of BV-related
94 bacteria is connected to 3.4 times higher infertility risk [13]. Women with subclinical
95 PID show 40% lower pregnancy chances compared to those without it [12].

96 Substantial clinical evidence exists for the role of infections in infertility from
97 investigational surveys involving confirmatory tests. However, questionnaire-based
98 surveys for female infertility do not typically include queries regarding infection-
99 associated symptoms which can be self/clinically assessed. Hence, to understand the
100 landscape of infertility and the influence of infections on various reproductive health
101 parameters among female subjects in the rural setup, we designed a detailed

102 questionnaire that specifically addresses the gaps listed above by the inclusion of
103 detailed queries on infection-associated symptoms. We then conducted an
104 observational, cross-sectional survey at an OB & GYN hospital (mother and child care
105 hospital) in Warangal, India. The subjects included were mainly from rural and semi-
106 urban backgrounds. Our study provides evidence for usefulness of the questionnaire
107 designed by us as a valuable tool for self or clinical assessment of female reproductive
108 health and may help in timely prognosis/diagnosis of genital infections which may
109 further improve the management of reproductive health and fertility.

110

111 **Materials and Methods**

112 **Ethics statement**

113 The research was conducted in accordance with the ethical guidelines set forth by the
114 Indian Council of Medical Research (ICMR) for biomedical and health research
115 involving human participants [23]. The study was approved by the Institutional Human
116 Ethics Committee (IHEC) of Birla Institute of Technology and Sciences (BITS) Pilani
117 Hyderabad campus (Protocol number: BITS-HYD/IHEC/2022/01). All individuals who
118 participated in the study were fully informed about various aspects, including the
119 study's objectives, methodologies, sources of funding, potential conflicts of interest,
120 institutional affiliations of the researcher, anticipated benefits, potential risks, and the
121 discomfort they might experience. Their participation was contingent on obtaining their
122 informed consent. Furthermore, to safeguard patient confidentiality, we took measures
123 to de-identify patient information. This included the removal of exact ages, which were
124 replaced with age ranges, and the omission of exact dates or photographs during
125 presentation of the data (See **Supplementary Material 1** for patient consent form).

126

127 **Study design, inclusion/exclusion criteria, and enrolment**

128 The observational, cross-sectional survey was conducted in Curewell Hospital,
129 Warangal, Telangana, India. Subject recruitment for the study was done based on the
130 gynecologist's assessment. Subjects were enrolled in the study based on the
131 inclusion/exclusion (I/E) criteria. In this study, female subjects (18-45 years) visiting
132 the clinic for infertility treatment (along with their male partners) were enrolled. Female
133 subjects outside the age group of 18-45 years were excluded from this study. Subjects
134 (couples) with complaints of infertility (not getting conceived for a duration of ≥ 12
135 months) were classified into the infertile group. Infertile subjects were further stratified
136 into primary (no live birth) and secondary infertility cases (at least one live birth).
137 Females with regular menstrual cycles and no recent history of infertility or genital
138 infection were classified into the healthy control group. Subjects diagnosed with
139 Human Papillomavirus (HPV), Human Immunodeficiency virus (HIV), and Hepatitis C
140 virus (HCV), and/or undergoing any antibiotic or hormonal therapy or *in vitro*
141 fertilization (IVF) treatment, were excluded from this study.

142

143 **Study Population and questionnaire-based data collection**

144 The sample size ($n = 97$) was determined by the help of formula $n = \frac{DEFF * Np(1-p)}{[(d^2/Z^2_{1-\alpha/2} * (N-1) + p(1-p))]}$, where n = sample size, DEFF = design effect, N =
145 population size (10^7), p = estimated proportion ($6.7\% \pm 5$), $q = 1-p$, d = desired absolute
146 precision (5%) or absolute level of precision, achieving a confidence level of 95% [24,
147 25]. Hence, a total of 100 female subjects were enrolled for this study based on I/E
148 criteria defined above following the informed consent. These subjects were further
149 allocated into groups (infertile and healthy) based on their fertility status (**Figure 1** for
150 study outline). The subjects in each group were assessed on a single time-point using
151

152 a detailed questionnaire. The questionnaire (**Supplementary Material 2**) is designed
153 to collect a comprehensive data on the female subjects included a variety of
154 parameters (**Supplementary Material 3, Table S1**). The study solely assessed the
155 existing information provided by the subjects (including previous test reports) and did
156 not involve collection of any new samples or performance of any new tests.

157

158 **Data handling and statistical analysis.** The data was collected through
159 questionnaire followed by digital recording into Microsoft (MS) Excel sheet via Google
160 forms. For the purpose of analysis, the data sets were simplified into a multinomial
161 format (Yes/No/No data). Data was plotted using MS Excel. Data analysis for
162 calculation of the frequency distribution and correlation (Phi coefficient) was performed
163 using IBM SPSS Statistics for Windows, Version 25.0., IBM Corp., Chicago, ILSPSS
164 amongst multiple parameters listed in **Table S1**. Data is reported as per the
165 STrengthening the Reporting of OBservational studies in Epidemiology (STROBE)
166 guidelines (<https://www.strobe-statement.org/>).

167

168 **Results**

169 ***Landscape of female Infertility and other reproductive health-related conditions***

170 A comprehensive questionnaire-based cross-sectional study is carried out to identify
171 the most significant parameters associated with subfertility, infertility (primary and
172 secondary), or conditions like pre-term birth, spontaneous abortions, medical
173 termination of pregnancy, and ectopic pregnancy in females. Out of the 100 subjects
174 assessed, 62 were categorized into the infertile group and 38 were healthy subjects
175 with no history of infertility or menstrual disorders (**Figure 1**). Amongst the infertile
176 group, only female infertility (39%) with healthy and fertile male spouses,

177 predominated the assessed population (**Figure 2A**). Infertility due to only male factors
178 with apparently healthy/fertile females represented only 2% of the study population
179 (**Figure 2A**). Female infertility is seen in 60% of the total study population including
180 21% of cases contributed by both male and female infertility (**Figure 2A**). Out of the
181 total 62 infertility cases, 90% are diagnosed with primary infertility, rest 10% are cases
182 of secondary infertility (**Figure 2B**). Our study highlights an early onset of female
183 infertility as young as ≤ 20 years of age (**Figure 2C**), with predominance of both
184 primary and secondary infertility in the age group of 21-30 years (**Figure 2C**). Among
185 62 infertility cases, ~74% failed to conceive even once, and a large proportion of ~23%
186 suffered from spontaneous abortions/have undergone medical termination of
187 pregnancy (MTP) (**Figure 2D**). Ectopic pregnancies were also observed in ~3% of
188 cases, however, no pre-term birth cases were observed in this study population
189 (**Figure 2D**). Age distribution of these failed pregnancies, reveals an early occurrence
190 in the age group of 21-25 years (**Figure 2E**).

191

192 **Genital infections- a major but neglected contributor to female infertility**

193 Among the various parameters assessed in females belonging to the infertility group,
194 incidence of genital infections (symptomatic and/or confirmed diagnosis) were
195 thoroughly investigated in this study, such as vaginitis (vaginal itching, burning and
196 discharge), PID, confirmed/symptomatic cases of UTIs (painful micturition/burning
197 sensation on micturition), TB positivity (based on tuberculin test/ QuantiFERON-TB
198 Gold/TB molecular diagnosis using PCR or TB culture test), cervicitis (cervical
199 inflammation) and dyspareunia (painful intercourse) (**Table S1 and S2A**).
200 Surprisingly, a large proportion of ~27% of infertile females show one or more signs of
201 infection-related symptoms (**Figure 3A, Table S2A**). The major symptoms observed

202 in these subjects are vaginitis (~18%), PID (~26%), dyspareunia (~11%), and 2
203 confirmed cases of pulmonary TB (~3.2%) (**Figure 3B, Table S2A**). Interestingly, the
204 analysis of questionnaire data reveals that confirmatory detection of infections has
205 largely been overlooked and is not typically included in the routine check-ups involved
206 in infertility management. The diagnosis is simply based on visible signs of genital
207 infections listed above. Hence, the detection of genital infections may prove to be a
208 highly valuable prognostic and diagnostic marker with significant relevance in the early
209 management of female infertility.

210 **Menstrual Health- a non-invasive prognostic marker of infertility**

211 Menstrual irregularities appear to be the predominant symptoms observed in the case
212 of females in the infertile group (~42%, **Figure 4A, Table S2A and S2B**). Menstrual
213 irregularities were further stratified into various categories such as menorrhagia (heavy
214 and prolonged bleeding), dysmenorrhoea (painful periods with cramps), amenorrhoea
215 (absence of periods), metrorrhagia (spot bleeding in between the periods) and
216 oligomenorrhoea (irregular periods or inconsistent blood flow). Among these
217 symptoms, amenorrhoea (~13%), metrorrhagia (~8%), and oligomenorrhoeae (~15%)
218 were evident only in the case of infertile subjects (**Figure 4B, Table S2A and S2B**).
219 However, symptoms such as menorrhagia (~34% vs. ~24% in infertile vs. healthy) and
220 dysmenorrhoea (~65% vs. ~29% in infertile vs. healthy) were observed both in healthy
221 and infertile subjects, though a larger proportion is observed in the infertile group
222 (**Figure 4B, Table S2A, and S2B**).

223

224 **Influence of physical health and lifestyle on infertility**

225 Out of the 100 subjects, 63% of women report a lack of exercise in their daily routine.
226 On further stratifying the data based on fertility status, a larger proportion of infertile

227 females (n = 40, 65% of the infertile group) reported lack of exercise (**Figure 5A, Table**
228 **S2A**). On further looking into the BMI status, all the females with low BMI (BMI < 18,
229 7% of the total study population) are infertile. Amongst the high BMI population, 10%
230 are infertile (**Figure 5B, Table S2C**).

231

232

233 **Spectrum of reproductive tract anomalies in infertile females**

234 We next assessed the spectrum of anomalies in the female reproductive tract in
235 infertile subjects. Among the various anomalies, PCOS and PCOD are the most
236 prominent pathological sequelae observed in infertile subjects (n = 19, ~31%) (**Figure**
237 **6, Table S2A**). The other prominent symptoms include fallopian tube blockage (n = 5,
238 ~8%) and a variety of endometrial disorders, such as secretory/proliferative/thickened
239 endometrium/hyperplasia/cysts (n = 4; ~7%), and endometriosis (n = 2, ~3%) (**Figure**
240 **6, Table S2A**). Unlike these symptoms, only one case of anovulation and ovarian
241 teratoma is observed in the infertile group (**Figure 6, Table S2A**).

242

243 **Hormonal perturbations in infertile females**

244 We next attempted to understand the changes in reproductive hormones in women
245 experiencing infertility. We compared and categorized the hormonal profiles of the
246 infertile subjects into low, high, and normal in the case of luteinizing hormone (LH) and
247 follicle-stimulating hormone (FSH). In the case of anti-Mullerian hormone (AMH) and
248 prolactin, data was stratified into abnormal (high) and normal. In the majority of the
249 cases, data for hormone profiles is not available (**Table S2D**). Although 58% of the
250 infertile subjects were tested for FSH, no specific pattern is observed concerning
251 infertility (**Figure 7, Table S2D**). For other hormones, data is available only in < 23%

252 of the infertile subjects, and no conclusive inference concerning fertility status could
253 be drawn (**Figure 7, Table S2D**).

254

255 **Male infertility and semen abnormalities in the infertile group**

256 Among the 62 infertile couples, a large proportion of male counterparts (n = 23, 37%)
257 presented with a variety of semen abnormalities (**Figure 8A**), such as, oligospermia
258 (low sperm count), low sperm DNA integrity (SDI), asthenozoospermia (AS) or low
259 sperm motility, teratozoospermia (high TZI index > 1.6) indicating presence of
260 abnormal shaped sperms (often linked with infection, injury or smoking), pyospermia
261 (presence of pus cells in semen), hypospermia (low volume of semen) and
262 hyperviscosity (**Figure 8B, Table S2A**). The most predominant abnormalities are
263 oligospermia (21%), asthenozoospermia (23%), and teratozoospermia (~ 15%). A few
264 cases of pyospermia (8.1%) and hyperviscosity (5%) are also observed indicative of
265 infection or high levels of seminal leukocytes (**Figure 8B, Table S2A**) also indicated
266 previously [26, 27].

267

268 **Multivariate correlation analysis among various parameters**

269 The major objective of this study is to identify the most significant parameters (**Table**
270 **S1**) that impact fertility and reproductive health in females. We also wanted to assess
271 if changes in these critical female parameters co-occur/correlate with the reduced
272 sperm/semen quality in males. We stratified the parameters into various categories
273 such as (a) menstrual disorders (**Table S2A and S2B**), (b) reproductive tract
274 anomalies such as endometriosis, other endometrial disorders (e.g.
275 thickened/secretory/proliferative endometrium/hyperplasia/cysts), fallopian tube or
276 uterine blockages, PCOS/PCOD, anovulation and ovarian cysts/teratoma (**Table**

277 **S2A**), (c) genital infection associated symptoms/confirmed diagnosis of infections like
278 TB/UTIs (**Table S2A**), (d) physiological parameters such as reproductive hormones
279 (FSH, LH, Prolactin, AMH) (**Table S2D**), (e) physical parameters and lifestyles, such
280 as weight, height, BMI and exercise routine (**Table S2A and S2C**) and (f) male sperm
281 and semen abnormalities (**Table S2A**). To derive the correlations between various
282 parameters, we performed multivariate correlation analysis (Phi correlation) [28-30].

283 We observe a highly significant and very strong correlation between parameters
284 related to genital infection-associated symptoms (or confirmed diagnosis) and
285 menstrual disorders such as oligomenorrhoea, amenorrhoea, metrorrhagia, and
286 dysmenorrhoea. (**Figures 9 and 10**). Further, a very strong and significant correlation
287 was observed between genital infections and perturbations in the female reproductive
288 hormones such as LH (**Figures 9 and 10**). The presence of infection-associated
289 symptoms also is strongly correlated with the occurrence of PCOS and PCOD, uterine
290 and tubal blockage, ovarian cysts, and endometrial disorders (**Figures 9 and 10**).

291 We next assessed if female genital infections correlate/co-occur with
292 abnormalities in the male semen and sperm profile. Our study suggests a very strong
293 and significant correlation of female genital infections with the occurrence of
294 teratozoospermia, pyospermia, and hyperviscosity of semen and a strong correlation
295 with asthenozoospermia. The abnormalities observed in male partners of infertile
296 females in this study concur well with the previously reported sperm abnormalities
297 during male genital infections [26, 27], however, no confirmatory diagnostic reports
298 were available to verify the nature of infections in these males (**Figure 9 and 10**).
299 Another key finding is a very strong and significant correlation between male
300 semen/sperm abnormalities characteristic of infections, such as low sperm DNA
301 integrity, asthenozoospermia, teratozoospermia, pyospermia and hyperviscosity with

302 female disorders such as occurrence of PCOS and PCOD, uterine and tubal blockage,
303 oligomenorrhoeae, amenorrhoea, metrorrhagia & dysmenorrhoea (**Figure 9 and 10**).
304 These observations highlight that transmission of genital infections between sexual
305 partners could potentially influence female menstrual health and fertility in both males
306 and females. Male factors are also strongly correlated with hormonal perturbations in
307 infertile females such as FSH, LH, and AMH (**Figures 9 and 10**).

308 Among other parameters, we observe a strong and significant correlation
309 between reproductive tract anomalies such as PCOS and PCOD with the occurrence
310 of menstrual disorders such as amenorrhoea (**Figures 9 and 10**). We also observe
311 endometrial disorders to impact menstrual health and are significantly correlated with
312 menorrhagia. We next assessed if the reproductive tract anomalies are linked with
313 reproductive hormones. We observe a strong and significant correlation between
314 ovarian cysts with AMH and anovulation with FSH, LH, and prolactin (**Figures 9 and**
315 **10**). In addition, uterine and tubal blockage are strongly correlated with prolactin, LH,
316 and AMH levels (**Figures 9 and 10**). However, one limitation of the data collected was
317 the absence of reports corresponding to female reproductive hormones in a large
318 number of cases (**Figure 7, Table S2D**).

319 Peculiarly, we observe a very strong and significant correlation between BMI in
320 females and genital infection-associated symptoms (such as
321 dyspareunia/cervicitis/vaginitis), menstrual disorders (such as menorrhagia), and
322 reproductive hormones (such as LH) (**Figure 9 and 10**).

323

324 **Discussion & Conclusion**

325 Remarkably, our investigation revealed that genital infections are often
326 overlooked during pregnancy or in women of reproductive age, indicating a glaring

327 gap in current healthcare practices and a significant lack of robust point-of-care (POC)
328 diagnostic tools in rural areas for detecting genital infections, including TB. Hence,
329 infertile women are typically treated primarily with hormones (Letrozole or clomiphene)
330 to improve ovulation, hormonal stimulation, and improvement of menstrual health and
331 are not treated for infections unless there are visible signs. As a result, asymptomatic
332 females remain undiagnosed for infections and do not receive appropriate health care
333 promptly. This prolonged lack of diagnosis and treatment can lead to chronic infections
334 and consequential pathological sequelae, ultimately resulting in infertility.

335 One of the most striking revelations from our study was the early onset of
336 infertility, occurring between 18 to 25 years of age. This suggests that many affected
337 individuals might have experienced mild or chronic symptoms post-puberty, which
338 remained undiagnosed and untreated. Importantly, a substantial portion of these
339 patients exhibited classical signs of infection (27%), while 73% were rendered
340 ineligible for confirmatory diagnostic tests due to a lack of classical symptoms of
341 infections. This underscores the urgent need for more comprehensive screening
342 strategies. We then uncovered a range of reproductive tract anomalies in infertile
343 females, including signs of PCOD/PCOS, tubal blockage, and smaller percentages
344 with conditions such as endometriosis, anovulation, uterine fibroids, and ovarian cysts.
345 This diversity of conditions makes it challenging for clinicians to establish a clear link
346 between these disorders and genital infections.

347 Furthermore, we observed a very strong and significant correlation between
348 genital infections and both physiological (hormonal profiles and BMI) and pathological
349 effects on female reproductive health (reproductive anomalies and menstrual
350 disorders) and sperm/semen quality in the case of males. Hence, detecting and
351 treating these infections is crucial not only for improving female reproductive health

352 but also for enhancing the success rate of fertility treatments, including assisted
353 reproductive technologies (ART). This suggests a potential link between poor lifestyle
354 habits and these health issues, similar to associations found with diabetes, obesity,
355 and PCOS/PCOD [31, 32] .

356 Diagnosing genital infection in case of TB, BV, candidiasis, PID, and
357 endometritis can be challenging due to varying, mild, or absent symptoms [13].
358 Moreover, identifying upper reproductive tract pathogens (endometrial/tubal/ovarian)
359 through microbial culture could be challenging requiring invasive sampling and there
360 is also the risk of vaginal and/or cervical pathogens contaminating these samples [13,
361 20-22]. Therefore, a modest clinical suspicion of genital infection is critical to identify
362 women at risk to prompt them for further detailed clinical investigations [33]. The
363 comprehensive questionnaire or survey-based approach as designed by us in this
364 study could address this gap and help in patient stratification for downstream
365 confirmatory diagnosis and treatments. On confirmatory diagnosis, treatment for
366 infections using suitable antimicrobials has shown benefits in terms of improving
367 symptoms and fertility outcomes [20-22, 34, 35]. Asymptomatic patients with chronic
368 endometrial disorders and unexplained infertility, recurrent implantation failures,
369 miscarriages, or intrauterine infections in previous pregnancies (like chorioamnionitis
370 or deciduitis), should also be considered for confirmatory diagnosis for infections.

371 Hence, we stress the potential of utilizing questionnaires for self/clinical
372 assessment, possibly through survey forms/user-friendly phone or web applications in
373 regional languages. This innovative strategy will also empower women from various
374 backgrounds to report reproductive health issues at an early stage, leading to timely
375 diagnosis and treatment thereby preventing chronic infections and long-term damage
376 in the form of infertility. This may also prevent medical poverty associated with

377 exorbitant treatment costs linked with ART. Our study also highlights an urgent need
378 for improvement in point-of-care (POC) diagnostic tools, increased awareness, and a
379 more holistic approach to tackle genital infections in the context of infertility. By
380 bridging these gaps, we can make significant strides in enhancing reproductive health
381 outcomes for women in rural and semi-urban settings, especially low and middle
382 income countries, promoting overall well-being and fertility.

383 **Author Contribution**

384 NP and RJD have conceived and designed the project, performed data mining,
385 analyzed the results, designed figures as well written and edited the manuscript. NP
386 collected the data at the clinic. US (epidemiologist) performed the statistical analysis.
387 RJD (microbiologist and biochemist), MJ (medical microbiologist), and VH (OB &
388 Gynaecologist, Curewell Hospital) provided overall supervision and coordination
389 during data collection at the clinical site. VH contributed to the enrolment of subjects
390 and patient stratification based on their fertility status. RJD received the funding. All
391 the authors reviewed and edited the manuscript.

392

393 **Funding**

394 Source of financial support in the form of grants:

- 395 1. Indian Council of Medical Research (ICMR), Govt. of India, Senior Research
396 Fellowship (RBMH/FW/2019/13) awarded to Naresh Patnaik (2019-2022).
- 397 2. Research Initiation Grant (RIG) and Centre for Human Disease Research (CHDR)
398 programs intramurally funded by Birla Institute of Science and Technology (BITS)
399 Pilani, Hyderabad campus, India to Ruchi Jain Dey (June 2018- March 2023).
- 400 3. Ramalingaswami Re-entry fellowship (BT/RLF/Re-entry/18/2016) awarded to
401 Ruchi Jain Dey (May 2018- April 2023).

402

403 **Acknowledgments**

404 RJD and NP are thankful to Amancha Sireesha for technical support and to the medical
405 staff at Curewell Hospital for support during the primary assessment and stratification
406 of subjects.

407

408 **Data availability statement**

409 All data that supports the findings of this study are available from the corresponding
410 author upon reasonable request.

411

412 **Conflict of Interest Statement**

413 The authors declare no conflict of interest.

414

415 **Supplementary Materials:** Supplementary materials contain the following:

416 **Supplementary Material 1 – Patient consent form**

417 **Supplementary Material 2 – Patient Questionnaire**

418 **Supplementary Material 3 - Tables S1-S2 (A, B, C and D)**

419

420 **References**

- 421 [1] Halleran M, Chernoff A, Gordon JL: Fertility Knowledge Among Women Struggling
422 to Conceive Without Medical Intervention: A Brief Report. *Front Glob Womens Health*
423 2022;3: 828052.
- 424 [2] Njagi P, Groot W, Arsenijevic J, Dyer S, Mburu G, Kiarie J: Financial costs of
425 assisted reproductive technology for patients in low- and middle-income countries: a
426 systematic review. *Hum Reprod Open* 2023;2023(2): hoad007.
- 427 [3] WHO. [https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-](https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility#:~:text=Large%20numbers%20of%20people%20are,report%20published%20today%20by%20WHO)
428 [by-](#)
429 [infertility#:~:text=Large%20numbers%20of%20people%20are,report%20published%20today%20by%20WHO](#). Published 2023. Accessed 4th April 2023.
- 430
431 [4] Wu J, Li D, Liu X, Li Q, He X, Wei J, et al.: IDDB: a comprehensive resource
432 featuring genes, variants and characteristics associated with infertility. *Nucleic Acids*
433 *Research* 2020;49(D1): D1218-D1224.
- 434 [5] Sharma JB, Dharmendra S, Agarwal S, Sharma E: Genital tuberculosis and
435 infertility. *Fertility Science and Research* 2016;3(1): 6.
- 436 [6] Deshpande PS, Gupta AS: Causes and prevalence of factors causing infertility in
437 a public health facility. *Journal of human reproductive sciences* 2019;12(4): 287.
- 438 [7] Allsworth JE, Peipert JF: Prevalence of bacterial vaginosis: 2001–2004 national
439 health and nutrition examination survey data. *Obstetrics & Gynecology* 2007;109(1):
440 114-120.
- 441 [8] Dyer SJ, Patel M: The economic impact of infertility on women in developing
442 countries-a systematic review. *Facts, views & vision in ObGyn* 2012;4(2): 102.
- 443 [9] Saigal K, Dhawan B, Rawre J, Khanna N, Chaudhry R: Genital Mycoplasma and
444 Chlamydia trachomatis infections in patients with genital tract infections attending a

- 445 tertiary care hospital of North India. *Indian Journal of Pathology and Microbiology*
446 2016;59(2): 194.
- 447 [10] Dhawan B, Khullar S, Rawre J, Gupta S, Khanna N: Prevalence of genital
448 Chlamydia trachomatis at a tertiary care hospital in North India: A 10-year
449 observational study. *Indian Journal of Sexually Transmitted Diseases and AIDS*
450 2023;44(1): 104.
- 451 [11] Haggerty CL, Totten PA, Tang G, Astete SG, Ferris MJ, Norori J, et al.:
452 Identification of novel microbes associated with pelvic inflammatory disease and
453 infertility. *Sexually transmitted infections* 2016;92(6): 441-446.
- 454 [12] Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL: Subclinical pelvic
455 inflammatory disease and infertility. *Obstetrics & Gynecology* 2012;120(1): 37-43.
- 456 [13] Cicinelli E, Matteo M, Tinelli R, Lepera A, Alfonso R, Indraccolo U, et al.:
457 Prevalence of chronic endometritis in repeated unexplained implantation failure and
458 the IVF success rate after antibiotic therapy. *Human reproduction* 2015;30(2): 323-
459 330.
- 460 [14] Jirge P, Chougule S, Keni A, Kumar S, Modi D: Latent genital tuberculosis
461 adversely affects the ovarian reserve in infertile women. *Human Reproduction*
462 2018;33(7): 1262-1269.
- 463 [15] Jirge PR: Effect of genital tuberculosis on ovarian reserve. *US Endocrinology*
464 2020;16: 104-108.
- 465 [16] Sharma J, Sharma E, Sharma S, Dharmendra S: Recent advances in diagnosis
466 and management of female genital tuberculosis. *The Journal of Obstetrics and*
467 *Gynecology of India* 2021;71(5): 476-487.

- 468 [17] Zahoor D, Bhat MM, Kanth F, Farhana A: Prevalence of genital tuberculosis in
469 infertile women; a study from a Tertiary Care Center in North India. *IJCMR* 2019;6(6):
470 F1-F3.
- 471 [18] Agarwal S, Chauhan J, Vacchani A, Ahir KK: A study on co-relation of infertility
472 and female genital tuberculosis. *National Journal of Medical Research* 2016;6(02):
473 151-154.
- 474 [19] Sharma D, Depan A, Yadav K, Narayan S, Sharma A: Prevalence of female genital
475 tract tuberculosis in suspected cases attending Gynecology OPD at tertiary centre by
476 various diagnostic methods and comparative analysis. *International Journal of*
477 *Reproduction, Contraception, Obstetrics and Gynecology* 2019;8(6): 2286-2293.
- 478 [20] Sharma JB, Sharma E, Sharma S, Dharmendra S: Female genital tuberculosis:
479 Revisited. *The Indian journal of medical research* 2018;148(Suppl 1): S71.
- 480 [21] Tripathy SN, Tripathy SN: Infertility and pregnancy outcome in female genital
481 tuberculosis. *International Journal of Gynecology & Obstetrics* 2002;76(2): 159-163.
- 482 [22] Tripathy S. Tuberculosis manual for obstetricians & gynecologists. JP Medical Ltd.
483 2015.
- 484 [23] ICMR. National ethical guidelines for biomedical and health research involving
485 human participants. In: Unit IB, ed. New Delhi: Director General ICMR. 2017.
- 486 [24] Patra S. Female Infertility in India: Causes, Treatment, and Fertility Impairment in
487 High Prevalence Districts. PAA 2017 Annual Meeting: PAA. 2017.
- 488 [25] Scheaffer RL, Mendenhall III W, Ott RL, Gerow KG. Elementary survey sampling.
489 Cengage Learning. 2011.
- 490 [26] Moretti E, Capitani S, Figura N, Pammolli A, Federico MG, Giannerini V, et al.:
491 The presence of bacteria species in semen and sperm quality. *Journal of assisted*
492 *reproduction and genetics* 2009;26: 47-56.

- 493 [27] Solomon M, Henkel R: Semen culture and the assessment of genitourinary tract
494 infections. *Indian Journal of Urology: IJU: Journal of the Urological Society of India*
495 2017;33(3): 188.
- 496 [28] Akoglu H: User's guide to correlation coefficients. *Turkish journal of emergency*
497 *medicine* 2018;18(3): 91-93.
- 498 [29] Hosseinzadeh-Shanjani Z, Hajimiri K, Rostami B, Ramazani S, Dadashi M:
499 Stress, anxiety, and depression levels among healthcare staff during the COVID-19
500 epidemic. *Basic and Clinical Neuroscience* 2020;11(2): 163.
- 501 [30] Kerur BM, Bhat BV, Harish B, Habeebullah S, Kumar CU: Maternal genital
502 bacteria and surface colonization in early neonatal sepsis. *The Indian journal of*
503 *pediatrics* 2006;73: 29-32.
- 504 [31] Sedighi S, Akbari SAA, Afrakhteh M, Esteki T, Majd HA, Mahmoodi Z: Comparison
505 of lifestyle in women with polycystic ovary syndrome and healthy women. *Global*
506 *journal of health science* 2015;7(1): 228.
- 507 [32] Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ: Lifestyle
508 changes in women with polycystic ovary syndrome. *Cochrane Database of Systematic*
509 *Reviews* 2019(3).
- 510 [33] Gallo MF, Macaluso M, Warner L, Fleenor ME, Hook III EW, Brill I, et al.: Bacterial
511 vaginosis, gonorrhea, and chlamydial infection among women attending a sexually
512 transmitted disease clinic: a longitudinal analysis of possible causal links. *Annals of*
513 *epidemiology* 2012;22(3): 213-220.
- 514 [34] Workowski KA, Bolan GA: Sexually transmitted diseases treatment guidelines,
515 2015. *MMWR Recomm Rep* 2015;64(Rr-03): 1-137.
- 516 [35] Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL: A randomized controlled
517 trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of

518 acute pelvic inflammatory disease. *Clinical Infectious Diseases* 2021;72(7): 1181-
519 1189.
520
521

522 **Figures**

523 **Figure 1. Study design flowchart.** The figure depicts an outline of the cross-sectional
524 survey conducted on infertile and healthy women to understand various parameters
525 influencing female fertility. In this study, 45 parameters (listed in Table S1) were
526 assessed to determine the frequency distribution and Phi correlation between different
527 parameters (as described in Table S2A-D and Figure 9, respectively).

528

529 **Figure 2. Population distribution and pattern analysis of female infertility and**
530 **other reproductive conditions.** A. Pie-chart shows the population distribution of
531 infertility amongst the assessed subjects (n = 100, 62 infertile couples, and 38 healthy
532 subjects). Out of 62 infertile couples, 60 cases were found to be associated with female
533 infertility (39 cases of only female infertility and 21 cases of both male and female
534 infertility), while 2 cases were identified as only male infertility leading to failure in
535 conception. B. Histogram shows the percentage distribution of primary and secondary
536 infertility amongst the 62 cases of infertility. C. Histogram shows the age-based
537 percentage population distribution (females) of primary and secondary infertility
538 amongst 62 cases of infertility. D. Pie chart shows the percentage population of
539 preterm birth, spontaneous abortions/medical termination of pregnancy (MTP), ectopic
540 pregnancy, and no conception amongst infertile females (n = 62). E. Age-based
541 population distribution of females (n = 62) experiencing preterm birth, spontaneous
542 abortions/MTP, ectopic pregnancy, and no conception.

543

544 **Figure 3. Contribution of genital infections to female infertility.** A. The Pie chart
545 shows the percentage of infertile females experiencing symptoms of genital infections
546 or confirmed diagnosis of infection. Reports suggest tuberculosis infection (based on

547 PPD tests) in 2 cases out of 62 subjects, while other infections are not identified during
548 diagnosis. B. Histogram shows population distribution of various genital infection-
549 related symptoms in females belonging to the infertile group (n =62, all cases of
550 infertility) and healthy group (n = 38). Healthy females do not show any symptoms of
551 infection, hence their bar is represented as "0".

552

553 **Figure 4. Female infertility and menstrual health.** A. Histogram shows the
554 percentage population distribution of females with respect to their menstrual health
555 based on the regularity of the menstrual cycle. B. Histogram shows population
556 distribution of various menstrual disorders among females belonging to infertile (n =62,
557 all cases of infertility) and healthy groups (n = 38). Infertile [%] = [No. of patients with
558 symptoms/Total infertility cases] *100. Healthy [%] = [No. of healthy subjects with
559 symptoms/Total no. of healthy subjects] *100.

560

561 **Figure 5. Contribution of lifestyle (exercise) and body mass index (BMI) to**
562 **female infertility.** A. Histogram shows the population distribution of all females
563 (healthy and infertile) based on their exercise routine. B. Histogram depicts the
564 population distribution of all females (healthy and infertile) with respect to their BMI.
565 (Normal BMI:18-25; Low BMI: <18; High BMI > 25).

566

567 **Figure 6. Female infertility and anatomical abnormalities of the reproductive**
568 **tract.** The histogram shows the population distribution of various anatomical
569 abnormalities of the female reproductive tract in infertile (n =62, all cases of infertility)
570 and healthy group (n = 38). Infertile [%] = [No. of patients with symptoms/Total infertility
571 cases] *100. Healthy [%] = [No. of healthy subjects with symptoms/Total no. of healthy

572 subjects]*100. Healthy females do not show any reproductive anomalies their bar is
573 represented as “0”.

574

575 **Figure 7. Female infertility and hormonal perturbations.** The histogram shows the
576 population distribution of females categorized under the infertile group (n = 62)
577 experiencing abnormal (high/low) levels of female reproductive hormones such as A.
578 FSH and LH; B. Prolactin and AMH. Hormone profiles of healthy subjects were not
579 available and hence were not considered during analysis. FSH [Normal: 4-12 IU/L;
580 high > 12 IU/L, low < 4 IU/L]; LH [Normal: 5-15 IU/L,; high > 15 IU/L, low < 5 IU/L];
581 Prolactin [Normal: ≤ 25 ng/ml; high > 25 ng/ml]; AMH [Normal: < 3 ng/ml; High > 3
582 ng/ml]

583

584 **Figure 8. Male infertility and semen abnormalities.** A. The histogram shows that
585 male infertility is primarily diagnosed with abnormal semen analysis in the infertility
586 group (n = 62) and healthy group (n = 38). B. Histogram shows the various semen
587 abnormalities prevalent in male infertile patients in the study. Infertile [%] = [No. of
588 male subjects with symptoms/Total infertility cases]*100. Healthy [%] = [No. of healthy
589 subjects with symptoms/Total no. of healthy subjects]*100. Males of healthy group do
590 not show any semen abnormalities and hence in absence of data, their bar is
591 represented as “0”.

592

593 **Figure 9. Correlation heat map between multiple variables.** The data gathered by
594 a questionnaire-based assessment of female patients is used for finding out the
595 correlation amongst the various parameters used for the assessment. A multivariate
596 correlation value (Phi correlation with the significance of correlation $p \leq 0.05$) was used

597 for generating this correlation heat map. (P1-P45 are the various parameters assessed
598 in this study, for description see supplementary table S1).

599

600 **Figure 10. Schematic diagram showing correlation between various fertility**
601 **parameters and their association with the incidence of genital infections.** The
602 correlation between various parameters is depicted schematically with the help of
603 bidirectional arrows of varying thickness corresponding to the strength of correlation
604 between these parameters. The correlations are deduced from the multivariate
605 correlation analysis (Phi correlation and the significance of the correlation). For details,
606 refer to the correlation heat map shown in Figure 9.

Enrolment

Recruitment/screening
(on Gynecologist's assessment)

Excluded –
I/E Criteria

Study enrolment for cross-sectional survey
(n=100)

Allocation






Allocation of enrolled subjects into two
groups *i.e.* Infertility (n1= 62) and Healthy
control (n2= 38)

Assessment


Questionnaire-based single time-point
assessment of the subjects using various
parameters (No sample collection)

Analysis


Graphs and plots (MS Excel)
Frequency and Correlation analysis (SPSS)




A




B





A




B




A**B**


Reproductive abnormality





A



B



A**B**


Φ	P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	P14	P15	P16	P17	P18	P19	P20	P21	P27	P28	P29	P30	P33	P34	P35	P36	P37	P38	P39	P40	P42	P43	P44			
P1		0.204	NS	NS	NS	NS	NS	0.320	0.320	NS	NS	NS	NS	NS	NS	NS	NS	0.471	NS	NS	NS	0.310	0.464	0.344	NS	NS	NS	NS	0.332	NS	NS	0.267	0.292	NS	NS				
P2			NS	0.233	NS	NS	NS	NS	NS	0.208	NS	NS	NS	NS	NS	NS	0.295	0.363	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.296	NS	NS	NS	NS	NS				
P3				0.271	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.295	NS	0.213	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS			
P4					0.289	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.221	0.609	0.484	0.273	0.368	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.294	NS	0.221	NS			
P5						0.205	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.269	NS	0.264	0.281	NS	NS	NS	NS	NS	NS	0.213	NS	NS	NS	NS	0.308	NS	NS	NS			
P6							NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS		
P7								NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.571	0.438	0.320	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P8									1.000	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.230	0.286	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P9										NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.230	0.286	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P10											0.492	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P11												NS	NS	0.700	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P12													NS	NS	NS	NS	NS	NS	NS	NS	0.230	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P13														NS	NS	NS	NS	NS	NS	NS	NS	0.402	0.312	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P14															NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P15																NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P16																	0.296	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
P17																		NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P18																			0.296	0.364	0.307	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P19																					0.327	0.406	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P20																						0.806	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P21																						NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
P27																																							
P28																																							
P29																																							
P30																																							
P33																																							
P34																																							
P35																																							
P36																																							
P37																																							
P38																																							
P39																																							
P40																																							
P42																																							
P43																																							
P44																																							

Φ > 0.25 (Very strong correlation), ρ ≤ 0.05

Φ > 0.15 (strong correlation), ρ ≤ 0.05

not significant (p > 0.05)

self correlation



↔ Very strong correlation with high significance

↔ Strong correlation with high significance